PEAK6 Investments LLC Sells 2,500 Shares of Twist Bioscience Co. (NASDAQ:TWST)

PEAK6 Investments LLC lessened its stake in Twist Bioscience Co. (NASDAQ:TWST) by 14.3% during the third quarter, Holdings Channel reports. The firm owned 15,000 shares of the company’s stock after selling 2,500 shares during the period. PEAK6 Investments LLC’s holdings in Twist Bioscience were worth $678,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its stake in Twist Bioscience by 7.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock valued at $1,103,000 after acquiring an additional 2,292 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Twist Bioscience by 1,896.8% during the second quarter. GAMMA Investing LLC now owns 3,754 shares of the company’s stock worth $185,000 after purchasing an additional 3,566 shares during the last quarter. CWM LLC grew its position in Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after purchasing an additional 524 shares in the last quarter. QRG Capital Management Inc. increased its stake in Twist Bioscience by 9.1% in the 2nd quarter. QRG Capital Management Inc. now owns 59,443 shares of the company’s stock valued at $2,929,000 after buying an additional 4,981 shares during the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares in the last quarter.

Insiders Place Their Bets

In other news, SVP Paula Green sold 1,057 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $43,928.92. Following the completion of the transaction, the senior vice president now directly owns 121,013 shares in the company, valued at approximately $5,029,300.28. This trade represents a 0.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dennis Cho sold 659 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $27,388.04. Following the sale, the insider now directly owns 94,481 shares in the company, valued at $3,926,630.36. This trade represents a 0.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock worth $4,391,151 in the last quarter. 3.92% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have weighed in on TWST. Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Scotiabank increased their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. Barclays reduced their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $51.00.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $50.61 on Wednesday. Twist Bioscience Co. has a fifty-two week low of $24.15 and a fifty-two week high of $60.90. The stock has a market cap of $3.00 billion, a PE ratio of -14.06 and a beta of 1.82. The stock has a fifty day moving average of $44.02 and a 200-day moving average of $46.27.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.